Showing 2001-2010 of 3239 results for "".
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever
- Resident Grants Available for Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20140701-resident_grants_available_for_cosmetic_surgery_forum/2459183/The Cosmetic Surgery Forum 2014, jointly sponsored by the Dulaney Foundation, Practical Dermatology® magazine and Cosmetic Surgery Forum, LLC, will take place December 3 through December 6, 2014 at The Palazzo Hotel Resort & Casino i
- Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiationshttps://practicaldermatology.com/news/20140530-valeant_and_pershing_square_make_revised_offer_for_allergan_contingent_on_good_faith_negotiations/2459224/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of
- Actavis Announces Acanya Gel Patent Challenge Settlementhttps://practicaldermatology.com/news/20140512-actavis_announces_acanya_gel_patent_challenge_settlement/2459243/
- Foamix Gains Five Additional US Patentshttps://practicaldermatology.com/news/20140421-foamix_gains_five_additional_us_patents/2459263/The United States Patent and Trademark Office (USPTO) issued Foamix five new patents covering its technologies. Foamix, a specialty pharmaceutical company, focuses on developing and commercializing proprietary topical foams. The additional five patents raises Foamix's number to 25 United
- Dermatology Resident Survey Finds Practice Gaps in Patient Safetyhttps://practicaldermatology.com/news/20140417-dermatology_resident_survey_finds_practice_gaps_in_patient_safety/2459267/A 2012 survey-based study of 142 dermatology residents from 44 US and Canadian residency programs was conducted to identify the source of clinical practices among dermatology residents that affect patient safety and determine the best approach for overcomi
- Nestle Skin Health Forming with Acquisition of Galdermahttps://practicaldermatology.com/news/20140214-nestl_skin_health_forming_with_acquisition_of_galderma/2459341/
- Ipsen Announces Clinical Results of Dysport Next Generationhttps://practicaldermatology.com/news/20140205-ipsen_announces_clinical_results_of_dysport_next_generation/2459348/